Novavax | NVAX - Operating Profit


Novavax reported $20.94M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Adma Biologics USD 50.29M 12.46M Mar/2026
Agenus USD 15.05M 656K Mar/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Cassava Sciences USD -11.17M 2.38M Mar/2026
Geron USD -236K 10.55M Mar/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
MannKind USD -68.23M 8.76M Jun/2026
Merck USD 840M 2.72B Jun/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD -815M 573M Jun/2026
Novartis USD 4.24B 171M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 667M 4.32B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026